JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

NCT06944470 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma
PROCEDURE: surgery
RADIATION: Radiochemotherapy
DRUG: JS207

Sponsor

Shanghai Junshi Bioscience Co., Ltd.